Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million to advance Dewpoint’s novel TDP-43 small-molecule condensate modulator for amyotrophic lateral sclerosis. Under terms of the deal, Boston-based Dewpoint will receive an undisclosed up-front payment and is eligible to receive R&D-based milestone payments up to $480 million. Upon reaching those milestones, Osaka, Japan-based MTPC will have an exclusive option to license the program and assume responsibility for global clinical development and commercialization. Dewpoint will also receive tiered royalties on net sales. Read More
Researchers from the Children's Hospital of Philadelphia presented data from a study that aimed to identify novel biologically relevant cell surface immunotherapeutic targets for neuroblastoma. Read More
With the aim of developing an effective and more tolerable conditioning for hematopoietic stem cell transplantation (HSCT), researchers from Molecular Partners AG applied the proprietary ankyrin repeat protein (DARPin) platform to generate a novel multi-specific Switch-DARPin candidate, MP-0621. Read More
Researchers from Bright Minds Biosciences Inc. presented data on the mechanism of action of BMB-101, a novel scaffold 5-HT2C Gq-protein biased designed to treat drug-resistant neurological disorders. Read More
Researchers from AUTOTAC Bio Inc. and affiliated organizations presented preclinical data for ATC-324, a novel autophagy-targeting chimera (AUTOTAC) designed to induce androgen receptor (AR) degradation. Read More
Nanjing Mingde New Drug Research Co. Ltd. has identified cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension. Read More
Sunshine Biopharma Inc. announced it has developed an orally active protease inhibitor that showed dose-dependent antiviral activity in mice infected with SARS-CoV-2. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Excellamol Inc. presented the design and preclinical characterization of XM161-SN38, a novel IL-13Rα2-targeting polypeptide-drug conjugate being evaluated for the treatment of gliomas. Read More
Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Additional early-stage research and drug discovery news in brief, from: Biovaxys Technology, Corvus Pharmaceuticals, Elevation Oncology, Modus Therapeutics, Nurexone Biologic, Poolbeg Pharma, Y-mAbs Therapeutics. Read More
